Literature DB >> 31081466

Benzodiazepines and non-benzodiazepine hypnotics - impact of a cluster adopted protocol on primary care prescribing.

Christopher J Weatherburn1.   

Abstract

BACKGROUND AND AIMS: Reduction of benzodiazepines and non-benzodiazepine hypnotics (BZDs and Z-drugs) prescribing is a priority. Dundee, Scotland, has a total of 25 general practices, split into four clusters. The cluster with the highest recorded prescribing of BZDs and Z-drugs adopted a prescribing protocol that aimed to reduce such prescribing. This paper evaluates the impact of this protocol.
METHODS: Quarterly prescribing data were obtained from Information Service Division, NHS Scotland from Q1 2015/16 to Q4 2017/18. Data were split into four clusters and standardised to Defined Daily Dose (DDDs) per 1000 registered patients. Interrupted time series (ITS) analysis was performed to assess prescribing one year after this protocol was introduced.
RESULTS: There was a crude reduction in prescribing of BZDs and Z-drugs across all GP practice clusters, but this related to an ongoing downward trend in prescribing. Allowing for this, in the cluster that adopted the protocol, ITS revealed there was no significant reduction attributable to the intervention in prescribing of DDD equivalent doses (-0.4%, 95% CI: -7.2 to 7.6).
CONCLUSIONS: Introduction of a cluster-wide prescribing protocol did not provide significant reduction of prescribing. Although crude figures might suggest an improvement, ITS analysis revealed this not to be the case.

Entities:  

Keywords:  Diazepam; benzodiazepines; interrupted time series analysis; prescriptions; primary health care

Mesh:

Substances:

Year:  2019        PMID: 31081466     DOI: 10.1177/0036933019849369

Source DB:  PubMed          Journal:  Scott Med J        ISSN: 0036-9330            Impact factor:   0.729


  1 in total

1.  Rationale and design of individualized quality improvement based on the Computer Analysing system to improve Stroke management quality Evaluation (CASE): a multicenter historically controlled study.

Authors:  Yi Chen; Wansi Zhong; Xiaoxian Gong; Haitao Hu; Shenqiang Yan; Xuting Zhang; Zhicai Chen; Ying Zhou; Min Lou
Journal:  Trials       Date:  2020-07-24       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.